Primus In News
Precision oncology gains ground as India clears targeted cancer therapies
25-12-2025
Nilaya Varma, Group CEO and Co-Founder,Primus Partners, highlights that the approvals represent a major step toward integrating outcome-based precision medicine into routine cancer care, with combination immunotherapies improving treatment outcomes for patient groups that previously had limited options.
Explore Related Insights
- Stock Market Highlights, July 30, 2025: Sensex settles 143 pts higher, Nifty tops 24850; Check gainers, losers | Closing Bell
- Budget may lay out Vision 2047 to build roads worth ₹20 trillion
- Regulatory reforms needed to achieve 500 GW clean energy target by 2030 Report
- Sudeep Pharma IPO gets fully subscribed on Day 1, GMP signals strong listing: Should you apply?
